Cardiac imaging has shed light on the possible mechanism behind the reduction in cardiovascular death and heart failure seen with an SGLT-2 inhibitor. Associate Professor Neale Cohen and colleagues from the Baker Heart and Diabetes Institute, Victoria have shown that the use of empagliflozin in patients with type 2 diabetes is associated with a reduction ...
Victorians reveal secret of SGLT2 cardiac benefits
By Mardi Chapman
28 Feb 2019